X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125156
https://www.fiercepharma.com/pharma/coherus-sells-lucentis-biosimilar-cimerli-sandoz-170m-focus-oncology
https://www.globenewswire.com//news-release/2023/10/04/2754586/33333/en/CIMERLI-ranibizumab-eqrn-Sales-Exceed-100-000-Doses-in-First-Year-of-Launch.html
https://www.midas-pharma.com/en/latest-activities/ranibizumab-launch/
https://endpts.com/outlook-therapeutics-stock-plunges-on-fda-rejection-for-lucentis-rival-in-wet-amd/
https://www.ema.europa.eu/en/documents/overview/ximluci-epar-medicine-overview_en.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761202
https://endpts.com/fda-issues-new-guidance-on-wet-amd-drug-development/
https://www.barrons.com/news/roche-novartis-win-appeal-against-record-french-fine-75577025
https://www.globenewswire.com/news-release/2023/02/13/2606609/33333/en/Coherus-Granted-Permanent-Product-Specific-Q-Code-for-CIMERLI-ranibizumab-eqrn-from-the-Centers-for-Medicare-and-Medicaid-Services.html
https://www.fiercepharma.com/pharma/proposal-congress-would-eliminate-interchangeable-status-biosimilars
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-november-9-2022-56129.pdf
https://endpts.com/roche-issues-voluntary-recall-for-susvimo-over-manufacturing-issue/
https://www.fiercepharma.com/manufacturing/roche-recalls-susvimo-implant-lucentis-leakage-fears-return-market-expected-within
https://www.pharmacompass.com/pdf/news/midass-ranivisio-ranibizumab-receives-approval-in-europe-17510.pdf
https://www.globenewswire.com/news-release/2022/09/19/2518203/0/en/Coherus-to-Launch-CIMERLI-ranibizumab-eqrn-in-the-United-States-on-October-3-2022.html
https://www.stada.com/blog/posts/2022/september/stada-and-xbrane-welcome-ema-positive-opinion-for-ranibizumab-biosimilar-candidate-ximluci
https://endpts.com/interchangeability-without-switching-studies-fda-explains-why-a-new-lucentis-biosimilar-may-be-a-game-changer/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761202
https://pharmaphorum.com/news/pressure-rises-on-lucentis-as-coherus-biosimilar-gets-fda-nod/
https://www.contractpharma.com/contents/view_breaking-news/2022-08-03/fda-approves-first-biosimilar-to-lucentis/?widget=listSection
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761165
https://www.fiercepharma.com/marketing/biogen-launches-first-us-biosimilar-samsung-bioepis-copycat-roches-lucentis-40-discount
https://www.lexblog.com/2022/05/19/teva-receives-approval-for-first-ophthalmology-biosimilar-in-europe/
https://www.fiercepharma.com/marketing/roches-susvimo-struggling-traction-eye-doctors
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761197
https://health.economictimes.indiatimes.com/news/pharma/intas-axantia-ink-agreement-to-commercialise-ranibizumab-in-middle-east/90658612
https://www.biospectrumasia.com/news/25/20015/indias-intas-pharma-signs-supply-agreement-for-ranibizumab-biosimilar-in-middle-east.html
https://www.globenewswire.com/news-release/2022/03/10/2400731/0/en/Health-Canada-Approves-Samsung-Bioepis-and-Biogen-s-BYOOVIZ-SB11-LUCENTIS-Biosimilar-ranibizumab.html
https://www.fiercepharma.com/pharma/novartis-targets-20-blockbuster-launches-by-2026-to-drive-growth-beyond-entresto-patent
https://www.prnewswire.com/news-releases/clinical-trial-research-at-wolfe-eye-clinic-contributes-to-fda-approval-of-genentechs-susvimo-a-first-of-its-kind-therapeutic-approach-for-wet-age-related-macular-degeneration-amd-301410349.html
https://www.fiercepharma.com/pharma/fda-green-lights-genentech-s-eye-implants-for-macular-degeneration-will-it-be-a-tough-sell
https://www.centerforbiosimilars.com/view/polpharma-executives-discuss-ranibizumab-biosimilar-and-other-product-candidates
https://www.globenewswire.com/news-release/2021/10/04/2307860/33333/en/Positive-Results-of-Clinical-Trial-Comparing-Coherus-Ranibizumab-Biosimilar-Candidate-CHS-201-to-Reference-Product-Lucentis-Ranibizumab-in-the-Treatment-of-Neovascular-Wet-Age-Rela.html
https://www.globenewswire.com/news-release/2021/10/04/2307755/0/en/Opthea-Opens-Patient-Recruitment-in-Europe-for-Pivotal-Phase-3-ShORe-and-COAST-Wet-AMD-Trials-of-OPT-302.html
https://www.businesswire.com/news/home/20211004005408/en/Polpharma-Biologics-Group-Announces-that-the-Biologics-License-Application-BLA-Submitted-by-its-Joint-Venture-Bioeq-for-its-Biosimilar-Ranibizumab-has-Been-Accepted-for-Review-by-the-U.S.-Food-and-Drug-Administration-FDA
https://www.globenewswire.com/news-release/2021/10/04/2307860/33333/en/Positive-Results-of-Clinical-Trial-Comparing-Coherus-Ranibizumab-Biosimilar-Candidate-CHS-201-to-Reference-Product-Lucentis-Ranibizumab-in-the-Treatment-of-Neovascular-Wet-Age-Rela.html
https://www.globenewswire.com/news-release/2021/10/04/2307755/0/en/Opthea-Opens-Patient-Recruitment-in-Europe-for-Pivotal-Phase-3-ShORe-and-COAST-Wet-AMD-Trials-of-OPT-302.html
https://www.fiercepharma.com/pharma-asia/fierce-pharma-asia-enhertu-s-big-win-biogen-samsung-s-lucentis-biosimilar-clover-s
https://www.fiercepharma.com/pharma/after-fda-nod-biogen-s-biosimilar-to-roche-s-blockbuster-lucentis-set-to-debut-next-year
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761202
https://www.api.polpharma.com/articles/september-2019-was-the-date-when-the-transformation-process-started-in-the-api-business-unit-of-polpharma
https://www.ema.europa.eu/en/documents/overview/byooviz-epar-medicine-overview_en.pdf
https://investors.biogen.com/news-releases/news-release-details/samsung-bioepis-and-biogen-announce-fda-filing-acceptance-sb11
Market Place
Share 
